Cell and Gene Therapy Bio-manufacturing Market Share, Size and Key Players Analysis 2026 to 2035
Segmentation of Cell and Gene Therapy Bio-manufacturing Market :
Cell and Gene Therapy Bio-manufacturing Market, By Product Type-
- Consumables
- Culture Supplements
- Media
- Serum
- Macronutrients
- Single-Use Liquids
- Cell Culture Reagents
- Cell Quantification Kits
- Culture Supplements
- Equipment
- Bioreactors/Fermenters
- Continuous Bioreactors
- Single-Use Bioreactors
- Mixing Systems
- Cell Counters
- Cell Sorters
- Centrifuges
- Incubators
- Biosafety Cabinets
- Freezers
- PCR Systems
- Transfection Systems
- Storage Tanks
- Others
- Bioreactors/Fermenters
- Software Solutions
Cell and Gene Therapy Bio-manufacturing Market, By Usage-
- Commercial Stage Manufacturing
- Research Stage Manufacturing
Cell and Gene Therapy Bio-manufacturing Market, By Application-
- Upstream Processing
- Formulation and Hydration
- Cell Culture Processing
- Harvesting
- Downstream Processing
- Separation and Filtration
- Fill and Finish Operations
Cell and Gene Therapy Bio-manufacturing Market, By End-User-
- Life Science Companies
- Equipment
- Consumables
- Software Solutions
- Contract Research Organizations (CROs)
- Equipment
- Consumables
- Software Solutions
- Contract Manufacturing Organizations (CMOs)
- Equipment
- Consumables
- Software Solutions
- Cell Banks
- Equipment
- Consumables
- Software Solutions
Cell and Gene Therapy Bio-manufacturing Market, By Region-
- North America-
- The US
- Canada
- Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
- Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Cell and Gene Therapy Biomanufacturing Market Snapshot
Chapter 4. Global Cell and Gene Therapy Biomanufacturing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Product Estimates & Trend Analysis
5.1. by Product & Market Share, 2025 & 2035
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2022 to 2035 for the following by Product:
5.2.1. Consumables
5.2.1.1. Culture Supplements
5.2.1.1.1. Media
5.2.1.1.2. Serum
5.2.1.1.3. Macronutrients
5.2.1.2. Single-Use Liquids
5.2.1.3. Cell Culture Reagents
5.2.1.4. Cell Quantification Kits
5.2.2. Equipment
5.2.2.1. Bioreactors/Fermenters
5.2.2.1.1. Continuous Bioreactors
5.2.2.1.2. Single-Use Bioreactors
5.2.2.2. Mixing Systems
5.2.2.3. Cell Counters
5.2.2.4. Cell Sorters
5.2.2.5. Centrifuges
5.2.2.6. Incubators
5.2.2.7. Biosafety Cabinets
5.2.2.8. Freezers
5.2.2.9. PCR Systems
5.2.2.10. Transfection Systems
5.2.2.11. Storage Tanks
5.2.2.12. Others
5.2.3. Software Solutions
Chapter 6. Market Segmentation 2: by Usage Estimates & Trend Analysis
6.1. by Usage & Market Share, 2025 & 2035
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2022 to 2035 for the following by Usage:
6.2.1. Commercial Stage Manufacturing
6.2.2. Research Stage Manufacturing
Chapter 7. Market Segmentation 3: by Application Estimates & Trend Analysis
7.1. by Application & Market Share, 2025 & 2035
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2022 to 2035 for the following by Application:
7.2.1. Upstream Processing
7.2.1.1. Formulation and Hydration
7.2.1.2. Cell Culture Processing
7.2.2. Harvesting
7.2.3. Downstream Processing
7.2.3.1. Separation and Filtration
7.2.3.2. Fill and Finish Operations
Chapter 8. Market Segmentation 4: by End-user Estimates & Trend Analysis
8.1. by End-user & Market Share, 2025 & 2035
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2022 to 2035 for the following by End-user:
8.2.1. Life Science Companies
8.2.1.1. Equipment
8.2.1.2. Consumables
8.2.1.3. Software Solutions
8.2.2. Contract Research Organizations (CROs)
8.2.2.1. Equipment
8.2.2.2. Consumables
8.2.2.3. Software Solutions
8.2.3. Contract Manufacturing Organizations (CMOs)
8.2.3.1. Equipment
8.2.3.2. Consumables
8.2.3.3. Software Solutions
8.2.4. Cell Banks
8.2.4.1. Equipment
8.2.4.2. Consumables
8.2.4.3. Software Solutions
Chapter 9. Cell and Gene Therapy Biomanufacturing Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Cell and Gene Therapy Biomanufacturing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2022-2035
9.1.2. North America Cell and Gene Therapy Biomanufacturing Market Revenue (US$ Million) Estimates and Forecasts by Usage, 2022-2035
9.1.3. North America Cell and Gene Therapy Biomanufacturing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2022-2035
9.1.4. North America Cell and Gene Therapy Biomanufacturing Market Revenue (US$ Million) Estimates and Forecasts by End-user, 2022-2035
9.1.5. North America Cell and Gene Therapy Biomanufacturing Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2035
9.2. Europe
9.2.1. Europe Cell and Gene Therapy Biomanufacturing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2022-2035
9.2.2. Europe Cell and Gene Therapy Biomanufacturing Market Revenue (US$ Million) Estimates and Forecasts by Usage, 2022-2035
9.2.3. Europe Cell and Gene Therapy Biomanufacturing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2022-2035
9.2.4. Europe Cell and Gene Therapy Biomanufacturing Market Revenue (US$ Million) Estimates and Forecasts by End-user, 2022-2035
9.2.5. Europe Cell and Gene Therapy Biomanufacturing Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2035
9.3. Asia Pacific
9.3.1. Asia Pacific Cell and Gene Therapy Biomanufacturing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2022-2035
9.3.2. Asia Pacific Cell and Gene Therapy Biomanufacturing Market Revenue (US$ Million) Estimates and Forecasts by Usage, 2022-2035
9.3.3. Asia-Pacific Cell and Gene Therapy Biomanufacturing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2022-2035
9.3.4. Asia-Pacific Cell and Gene Therapy Biomanufacturing Market Revenue (US$ Million) Estimates and Forecasts by End-user, 2022-2035
9.3.5. Asia Pacific Cell and Gene Therapy Biomanufacturing Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2035
9.4. Latin America
9.4.1. Latin America Cell and Gene Therapy Biomanufacturing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2022-2035
9.4.2. Latin America Cell and Gene Therapy Biomanufacturing Market Revenue (US$ Million) Estimates and Forecasts by Usage, 2022-2035
9.4.3. Latin America Cell and Gene Therapy Biomanufacturing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2022-2035
9.4.4. Latin America Cell and Gene Therapy Biomanufacturing Market Revenue (US$ Million) Estimates and Forecasts by End-user, 2022-2035
9.4.5. Latin America Cell and Gene Therapy Biomanufacturing Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2035
9.5. Middle East & Africa
9.5.1. Middle East & Africa Cell and Gene Therapy Biomanufacturing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2022-2035
9.5.2. Middle East & Africa Cell and Gene Therapy Biomanufacturing Market Revenue (US$ Million) Estimates and Forecasts by Usage, 2022-2035
9.5.3. Middle East & Africa Cell and Gene Therapy Biomanufacturing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2022-2035
9.5.4. Middle East & Africa Cell and Gene Therapy Biomanufacturing Market Revenue (US$ Million) Estimates and Forecasts by End-user, 2022-2035
9.5.5. Middle East & Africa Cell and Gene Therapy Biomanufacturing Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2035
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Becton, Dickinson and Company
10.2.2. Endress+Hauser Group Services AG (Analytik Jena GmbH)
10.2.3. Danaher Corporation
10.2.4. Bio-Rad Laboratories, Inc.
10.2.5. Bio-Techne Corporation
10.2.6. General Electric Company (G.E. Healthcare)
10.2.7. Getinge AB
10.2.8. Infors AG
10.2.9. Lonza Group Ltd
10.2.10. Merck KGaA
10.2.11. Miltenyi Biotec B.V. & Co. KG
10.2.12. PIERRE GUERIN
10.2.13. Sartorius AG (Sartorius Stedim Biotech S.A.)
10.2.14. Thermo Fisher Scientific Inc.
10.2.15. WuXi AppTec
10.2.16. Other Prominent Players
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Cell and Gene Therapy Bio-Manufacturing Market Size is valued at USD 15.22 Billion in 2025 and is predicted to reach USD 44.69 Billion by the year 2035
Cell and Gene Therapy Bio-manufacturing Market expected to grow at a 11.5% CAGR during the forecast period for 2026 to 2035
Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Danaher Corporation, Endress+Hauser Group Services AG (Analytik Jena GmbH), General Electric Company (G.E. Healthcare), Getinge AB, Infors AG, Lonza Group Ltd, Merck KGaA, Miltenyi Biotec B.V. & Co. K.G., PIERRE GUERIN, Sartorius AG (Sartorius Stedim Biotech S.A.), Thermo Fisher Scientific Inc., WuXi AppTec. and Others
Cell and gene therapy bio-manufacturing market is segmented on the basis of product type, usage, application, and end-user.
North America region is leading the Cell and gene therapy bio-manufacturing market.